Posts

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

/by

Authors: Russell K. Portenoy, Elena Doina Ganae-Motan, Silvia Allende, Ronald Yanagihara, et al
The Journal of Pain, May 2012
—
Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. Nabiximols (Nabiximols is the U.S. Adopted Name [USAN] for Sativex [GW Pharma Ltd, Wiltshire, U.K.], which does not yet have an INN), a novel cannabinoid formulation…

Read more

Cannabinoid-opioid interaction in chronic pain.

/by

Authors: D. I. Abrams, P. Couey, S. B. Shade, M. E. Kelly, N. L. Benowitz
Clinical Pharmacology & Therapeutics, December 2011
—
Cannabinoids and opioids share several pharmacologic properties and may act synergistically. The potential pharmacokinetics and the safety of the combination in humans are unknown. We therefore undertook a study to answer these questions. Twenty-one individuals with chronic pa…

Read more